SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
暂无分享,去创建一个
J. Bernhard | K. Zaman | R. Winterhalder | U. Hasler-Strub | C. Rochlitz | T. Ruhstaller | M. Borner | A. Wicki | R. Cathomas | T. Rordorf | R. V. Von Moos | D. Rauch | D. Bärtschi | A. Trojan | S. Anchisi | M. Vetter | K. Matter-Walstra | Kyung-Jae Na | M. Bigler | M. Küng | A. Müller